The board of directors of Sino Biopharmaceutical Limited announced that the randomised, open, positive drug-parallel controlled, multi-centre Phase III clinical study for the first-line treatment of.
The prevalence of Esophageal Squamous Cell Carcinoma has been rising since the past few years, which prompts the growing demand for the treatment options. The market is driven by the increasing
/PRNewswire/ DelveInsight s Esophageal Cancer Pipeline Insight – 2022 report provides comprehensive global coverage of available, marketed, and pipeline.